Methods and reagents suitable for in vitro diagnostic assay comprising a qualitative immunohistochemical assay using anti-Globo H antibodies and/or binding fragments thereof are provided. The method comprises the detection of Globo-H expression levels in formalin-fixed, paraffin-embedded (FFPE) cancer tissue using a visualization system. The Globo-H expression can be determined by using tumor scoring showing partial or complete staining at any intensity.

A method for pre-treatment identification of cancer patients that respond to anti-CLEVER-1 therapy comprising an administration of an agent capable of binding to CLEVER-1 in a patient. In the method. the presence of PD-L1 expressing cells and CLEVER-1 expressing cells is detected in a tumor sample obtained from a cancer patient. by immunohistochemistry staining by a PD-L1 specific antibody and a mouse monoclonal lgG2a kappa STAB-1 antibody (clone 4G9), and then a percentage of PD-L1 expressing cells from the total amount of viable cells present in the stained sample, and a percentage of intra-tumoral CLEVER-1 expressing cells from the total amount of viable intra-tumoral cells present in the stained sample. is calculated. A tumor sample which shows low percentage of PD-L1 expressing cells or not comprising PD-L1 expressing cells together with substantial percentage of CLEVER-1 expressing intra-tumoral cells is an indication that the cancer patient is responsive to the anti-CLEVER-1 therapy.

The disclosure relates to a sample image capturing system, including: a sample holding apparatus configured to hold a sample slide on which a sample film is applied; an imaging apparatus configured to capture the sample on the sample slide; a sample appearance image obtaining apparatus configured to obtain a sample appearance image, where the sample appearance image includes at least an appearance image of the sample film; and a controller configured to: obtain the sample appearance image, identify an appearance characteristic of the sample film based on the sample appearance image, determine a capturing parameter based on the appearance characteristic, and control the imaging apparatus to capture, with the capturing parameter, sample components on the sample slide. The disclosure further relates to a sample image capturing method and a computer-readable storage medium. The disclosure can use a characteristic of the appearance image to achieve accurate capturing of sample images.

The subject matter described herein provides methods for treating an autoimmune disease in a subject, comprising administering to the subject an effective amount of a conjugate that comprises an IGF-1R ligand, or portion or variant thereof, and a disease-modifying agent.

The present disclosure provides methods and systems for predicting a subject's diagnostic status with respect to a disease or disorder. The method may comprise staining a tooth, hair, or nail sample of the subject to produce a stained tooth sample, analyzing a fluorescence intensity spatially across the stained tooth, hair, or nail sample, and predicting a subject's diagnostic status with respect to a disease or disorder based at least in part on the analysis of the fluorescence intensity.

Aspects herein relate to methods, compositions, and systems directed to the discovery that TSG-6 secretion by cancer-associated fibroblasts (CAFs) in a tumor, in some instances, leads to a poor response to immune checkpoint therapies in the tumor. Inhibition of TSG-6 in certain cancers, in combination with immune checkpoint therapies, led to an improved therapeutic response to the immune checkpoint therapies. Such findings provide methods and compositions for diagnosing, prognosing, and treating certain cancers.

The present invention provides a method for selecting a cancer patient for whom a combination therapy with a retinoid and a cancer treatment agent is effective, which comprises a step of selecting a cancer patient having a malignant tumor with the infiltration of cancer-associated fibroblasts in the stroma. In addition, the present invention provides a medicament which comprises a cancer patient having a malignant tumor with the infiltration of cancer-associated fibroblasts in the stroma is a subject and is administered in combination of a retinoid and a cancer therapeutic agent.

The present disclosure relates to an engineered M13 bacteriophage displaying amyloidogenic peptide motifs from amyloid beta 42 (A42) at its surface. The present disclosure further relates to the use of the disclosed engineered M13 bacteriophage for detecting early species of A, namely oligomeric and fibrillar A, and preventing its aggregation promoting the inhibition of the progression of Alzheimer's disease and thus contributing to the treatment of this neurodegenerative disorder.

Disclosed are methods of treating of a subject having cancer comprising applying an alternating electric field to a target site of the subject for a period of time, wherein the target site comprises one or more cancer cells, wherein the subject has an isocitrate dehydrogenase mutation (IDHmut). Disclosed are methods of treating a subject comprising identifying a subject with an IDHmut; and applying an alternating electric field to a target site of the subject for a period of time, wherein the target site comprises one or more cancer cells.